新聞Exelis Inc. partners with United States Navy."During the past 33 months, Exelis has worked closely with the U.S. Navy to ensure our technology is ready for the next stage of this important program."
新聞Exelis Inc. launches Phase 1b clinical study results for the cabozantinib and atezolizumab.Exelis Inc. (NASDAQ:EXEL) has announced positive Phase 1b clinical study results for the cabozantinib (CABOMETYX®) and atezolizumab (TECENTRIQ®) combination in treating patients with metastatic/locally advanced solid tumors.
新聞Harris Corp. acquired Exelis Inc. on Jan 1st '15.SRI announced today the signing of a formal reseller agreement with Harris Corporation, who recently acquired Exelis Inc.
